Can dihydropyrimidine dehydrogenase impact 5-fluorouracil-based treatment?

This publication has 18 references indexed in Scilit:

• A National Cancer Institute of Canada Clinical Trials Group phase II study of eniluracil (776C85) and oral 5-fluorouracil in patients with advanced squamous cell head and neck cancer
  Published by Elsevier ,2001
• Nomenclature for human DPYD alleles
  Pharmacogenetics, 1998
• Dihydropyrimidine dehydrogenase pharmacogenetics in Caucasian subjects
  British Journal of Clinical Pharmacology, 1998
• Inter- and intraindividual variation in dihydropyrimidine dehydrogenase activity in peripheral blood mononuclear cells
  Cancer Chemotherapy and Pharmacology, 1997
• Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity.
  Journal of Clinical Investigation, 1996
• A role for dihydropyrimidine dehydrogenase and thymidylate synthase in tumour sensitivity to fluorouracil
  European Journal Of Cancer, 1994
• Potential importance of dihydropyrimidine dehydrogenase (DPD) in cancer chemotherapy
  Pharmacogenetics, 1994
• 5-Ethynyluracil (776C85): a potent modulator of the pharmacokinetics and antitumor efficacy of 5-fluorouracil.
  Proceedings of the National Academy of Sciences, 1993
• Clinical Pharmacology of 5-Fluorouracil
  Clinical Pharmacokinetics, 1989
• Circadian rhythm of rat liver dihydropyrimidine dehydrogenase
  Biochemical Pharmacology, 1988